AbCellera expands research collaboration with Teva
Collaboration extends initial partnership and aims to generate lead antibody candidates against membrane targets using AbCellera's antibody discovery platform…
List view / Grid view
Collaboration extends initial partnership and aims to generate lead antibody candidates against membrane targets using AbCellera's antibody discovery platform…
A preclinical candidate calcitonin gene-related peptide (CGRP) antagonist has been nominated for advancement into further preclinical studies as an investigational treatment for migraine.
3 February 2016 | By Victoria White
AbCellera will apply its high-throughput single cell antibody platform for the discovery of the rare monoclonal antibodies...
25 November 2015 | By Victoria White
The companies have entered an agreement to discover and develop novel, small-molecule CGRP antagonists for the treatment of migraine...
6 November 2015 | By SMi
Leading organizations in the Biosimilars Development sector will meet at Biosimilars and Biobetters USA 2015 – the must-attend premier industry event which will take place in Iselin this November...
7 October 2015 | By SMi Group
Leading organizations in the Biosimilars Development sector will meet at Biosimilars and Biobetters USA 2015 – the must-attend premier industry event which will take place in Iselin this November...
17 July 2015 | By Biosimilars and Biobetters
This year's conference will address recent regulatory updates, pharmacovigilance of biosimilars, patent litigation, market access & global market developments...
21 July 2014 | By Teva
...opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.
4 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities...
30 April 2014 | By Teva
Data provides promise for a twice-daily, acetaminophen-free hydrocodone designed with potential abuse-deterrent properties...
28 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced results from the Phase III SYNERGY trial...